La cadena de opciones muestra datos clave de las opciones de acciones de N2OFF a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para N2OFF..

N2OFF (NASDAQ:NITO) Bolsa, Cadena de Opciones

N2OFF

N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

NITO

TANH

Las acciones de materiales más sobrevendidas, con un RSI por debajo de 30, que podrían ofrecer oportunidades para inversores estratégicos.

3 acciones de materiales que podrían despegar en agosto

N2OFF Inc

NITORI HOLDINGS CO LTD by Nitori Holdings Co., Ltd.

Nitori Holdings Co Ltd

NITORI HOLDINGS CO U/ADR by Nitori Holdings Co., Ltd.

TD Bank Group ("TD" or the "Bank") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) announced today that it expects catastrophe claims of approximately $50 million after reinsurance and before tax to be reflected in the Bank's Wealth Management &amp; Insurance segment's second-quarter results.&nbsp;

TSX:TD

TD Bank Expects Catastrophe Claims Of ~$50M After Reinsurance And Before Tax To Be Reflected In The Bank's Wealth Management & Insurance Segment's Second-quarter Results.

BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">consensus of $126.87 million</a>.
The increase was primarily due to $134.2 million (+$45.3 million yoy) in Orladeyo&#8217;s net revenue in the first quarter of 2025, compared to $88.9 million in the first quarter of 2024 (+51.0 percent yoy).&nbsp;
Orladeyo&#8217;s net revenue increased to $134.24 million&nbsp;from <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190350/biocryst-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">$88.87 million a year ago</a>.
Net income for the first quarter of 2025 was $32 thousand, or $0.00 per share, compared to a net loss of $35.4 million, or $0.17 per share, for the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">first quarter of 2024</a>.&nbsp;
Operating income for the first quarter of 2025 was $21.2 million, compared to an operating loss of $14.5 million for the first quarter of 2024. Non-GAAP operating income, excluding stock-based compensation expense, was $42.6 million for the first quarter of 2025, compared to a non-GAAP operating loss of $0.8 million for the first quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45193720/immunitybio-slapped-with-fda-refusal-to-file-letter-for-expanded-use-of-its-bladder-cancer-drug" rel="noreferrer noopener">ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug</a>
Guidance: BioCryst increased its 2025 outlook for Orladeyo revenue to $580 million and $600 million <a target="_blank" href="https://www.benzinga.com/25/02/43918295/biocryst-pharmaceuticals-reveals-interim-data-from-orladeyo-pediatric-trial-reports-mixed-q4-earnings" rel="noreferrer noopener">from $535 million and $550 million</a>.
The company now expects full year 2025 operating expenses will be $440 million to $450 million (previously $425 million to $435 million).
The company is accelerating its expectation for sustainable profitability and positive cash flows by a year.
The company now expects to deliver net income and positive cash flows for the full year 2025 (previously, both were expected for the full year 2026).
Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash, and investments from year-end 2024 to year-end 2025, not including the impact of the $75 million Pharmakon prepayment made in April 2025.
Price Action:&nbsp;BCRX stock closed higher by 23.50% to $11.03&nbsp;on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45196561/loews-posts-mixed-q1-results-pipeline-strength-offsets-insurance-and-hotel-weakness" target="_blank" rel="noreferrer noopener">Loews Posts Mixed Q1 Results: Pipeline Strength Offsets Insurance And Hotel Weakness</a></li>
</ul>

Biotech

Earnings

Guidance

Health Care

Movers

General

BCRX

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

Franklin Resources Reports Preliminary Month-End AUM Of $1.53T At April 30, 2025, Compared To $1.54T At March 31, 2025

Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) reported financial results for the first quarter after the market close on Monday. Shares are moving lower after the company paused guidance. Here&#8217;s what you <a href="https://www.benzinga.com/pressreleases/25/05/b45206394/mattel-reports-first-quarter-2025-financial-results">need to know</a>.
Q1 Earnings: Toymaker Mattel reported first-quarter revenue of $827 million, beating analyst estimates of $786.01 million. The company reported a first-quarter adjusted loss of three cents per share, beating estimates for a loss of 10 cents per share, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 2% year-over-year, driven by a 3% increase in North America and a 1% increase in International. The company reported a first-quarter gross margin of 49.4%, up from 48% in the prior year&#8217;s quarter.
Mattel repurchased $160 million worth of shares in the quarter and ended the period with approximately $1.24 billion in cash and cash equivalents. The company said it was maintaining its $600 million share repurchase target for 2025. 
&#8220;This was a strong quarter for Mattel, with positive performance and continued operational excellence. Our brands are thriving, our products and experiences stand out in the marketplace, and our balance sheet gives us resilience and flexibility to execute our strategy,&#8221; said Ynon Kreiz, chairman and CEO of Mattel.
&#8220;As we navigate the current period of macro-economic volatility, we are adapting with speed, agility, and discipline. We expect not only to manage through this period but strengthen our competitive position.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/05/45209366/clorox-stock-drops-after-worse-than-expected-q3-results-heightened-macroeconomic-uncertainties-lowered-sales-ceo-says">Clorox Stock Drops After Worse-Than-Expected Q3 Results: &#8216;Heightened Macroeconomic Uncertainties&#8217; Lowered Sales, CEO says</a>
Mattel said it will take mitigating actions designed to fully offset the potential incremental cost impact of tariffs on future performance, including accelerating diversification of its supply chain, optimizing product sourcing and mix and taking pricing actions where necessary. 
The company also announced plans to accelerate cost savings and is increasing its 2025 savings target from $60 million to $80 million. 
Mattel said it will pause its full-year 2025 guidance, given the &#8220;volatile macro-economic environment and evolving U.S. tariff landscape.&#8221; The company noted that it will provide guidance again when it has &#8220;sufficient visibility.&#8221;
Mattel executives are discussing details from the quarter on a conference call that kicked off at 5 p.m. ET.
MAT Price Action: <a href="http://benzinga.com/quote/mat">Mattel shares</a> were down 2.47% in Monday&#8217;s after-hours session, trading at $15.80 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/rblfmr">rblfmr</a>/Shutterstock.

After-Hours Center

Mattel Beats Q1 Estimates, Pauses Guidance Due To Tariffs, Plans Actions To Mitigate Cost Impacts

Celanese Announces Engineered Materials Price Increases; Price Increases Are Associated With Heightened Costs Of Product Movement And Inventory Repositioning, Plant Operational Expenses, Changing Trade Regulations, And Raw Materials; Increases Will Be Effective On June 1, 2025

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) announced today the pricing of three series of senior unsecured fixed rate notes for a total of $2.0 billion. These notes include $750.0 million of 5.350% notes due in 2028, $750.0 million of 5.625% notes due in 2030 and $500.0 million of 6.250% notes due in 2035. The offering is expected to settle on May 7, 2025.
GM intends to use the net proceeds from the sale of the notes for general corporate purposes, including to refinance a portion of the $1.25 billion outstanding of its 6.125% senior notes maturing on October 1, 2025, and fund a portion of the $1.8 billion five-year term loan it has agreed to make to Ultium Cells LLC, its joint venture with LG Energy Solution, to facilitate full voluntary prepayment of loans Ultium Cells LLC received under the U.S. Department of Energy's Advanced Technology Vehicles Manufacturing program.

Offerings

General Motors Announces The Pricing Of Three Series Of Senior Unsecured Fixed Rate Notes For A Total Of $2B

Citigroup analyst Stephen Trent maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Neutral and raises the price target from $4.25 to $5.

Price Target

Analyst Ratings

JBLU

Citigroup Maintains Neutral on JetBlue Airways, Raises Price Target to $5

Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 55.77 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $479.80 thousand which beat the analyst consensus estimate of $100.00 thousand by 379.80 percent. This is a 524.46 percent increase over sales of $76.83 thousand the same period last year.

Earnings Beats

Earnings Misses

CTNT

Cheetah Net Supply Chain Q1 EPS $(0.23) Misses $(0.21) Estimate, Sales $479.80K Beat $100.00K Estimate

Diamondback Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NYSE">FANG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/05/g45206097/diamondback-energy-inc-announces-first-quarter-2025-financial-and-operating-results">from the report. </a>
The Details: Diamondback Energy reported adjusted earnings of $4.54 per share, which beat the analyst consensus estimate of $4.13. Quarterly revenue clocked in at $4.05 billion, beating the $3.73 billion consensus estimate.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
For the first quarter, Diamondback Energy reported: 
<ul>
<li>Average oil production of 475.9 MBO/d (850.7 MBOE/d).</li>
<li>Net cash provided by operating activities of $2.4 billion; Operating Cash Flow Before Working Capital Changes of $2.5 billion.</li>
<li>Cash capital expenditures of $942 million.</li>
<li>Adjusted Free Cash Flow of $1.6 billion</li>
<li>Declared Q1 2025 base cash dividend of $1.00 per share payable on May&nbsp;22, 2025, implying a 2.9% annualized yield based on May&nbsp;2, 2025 closing share price of $136.81. </li>
</ul>
The company will host a conference call to discuss the results on Tuesday at 9 a.m. ET. 
Outlook: Diamondback Energy sees full-year 2025 oil production of 480 to 495 MBO/d (857-900 MBOE/d) and cash capital expenditures guidance of $3.4 billion to $3.8 billion.
FANG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Diamondback Energy stock was down 0.054% after-hours at $133.01 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Commodities

FANG

Diamondback Energy Reports Better-Than-Expected Q1: Details

Bain Capital Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCSF#NYSE">BCSF</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.47 by 6.38 percent. This is a 5.66 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $66.84 million which missed the analyst consensus estimate of $71.00 million by 5.86 percent. This is a 10.28 percent decrease over sales of $74.50 million the same period last year.

BCSF

Bain Capital Specialty Q1 EPS $0.50 Beats $0.47 Estimate, Sales $66.84M Miss $71.00M Estimate

FDA lifts clinical hold enabling resumption of clinical trials
FDA has granted a Type A Meeting to discuss path forward for BLA
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54249346&amp;newsitemid=20250505744665&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=1c32768a01374adbfe2795637b823f9c">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara's active Investigational New Drug (IND) applications for the EBVALLO&#x2122; (tabelecleucel) program.

ATRA

Atara Biotherapeutics Provides Regulatory Updates On EBVALLO; FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials; FDA Has Granted A Type A Meeting To Discuss Path Forward For BLA

Stock Split

RNAZ

TransCode Therapeutics Approved An Effective Time At 12:01 a.m. EST May 15, 2025, For Its 1-For-28 Reverse Stock Split

Citigroup analyst Kyle Menges maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Buy and raises the price target from $12 to $14.

Citigroup Maintains Buy on CNH Industrial, Raises Price Target to $14

Citigroup analyst Kyle Menges maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and raises the price target from $90 to $110.

AGCO

Citigroup Maintains Buy on AGCO, Raises Price Target to $110

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Neutral and lowers the price target from $10 to $9.5.

ARVN

Citigroup Maintains Neutral on Arvinas, Lowers Price Target to $9.5

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2025 GAAP EPS guidance from $6.75-$7.25 to $7.15-$7.65 vs $6.97 analyst estimate..

STRL

Sterling Infrastructure Raises FY2025 GAAP EPS Guidance From $6.75-$7.25 To $7.15-$7.65 vs $6.97 Est

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2025 Adj EPS guidance from $7.90-$8.40 to $8.40-$8.90 vs $7.27 analyst estimate. Raises FY2025 sales outlook from $2.00 billion-$2.15 billion to $2.05 billion-$2.15 billion vs $2.02 billion estimate.

CORRECTION: Sterling Infrastructure Raises FY2025 Adj EPS Guidance from $7.90-$8.40 to $8.40-$8.90 vs $7.27 Est; Raises FY2025 Sales Guidance from $2.00B-$2.15B to $2.05B-$2.15B vs $2.02B Est

Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.39%. Currently, Home Depot has a market capitalization of $359.57 billion. 
Buying $1000 In HD: If an investor had bought $1000 of HD stock 10 years ago, it would be worth $3,232.62 today based on a price of $361.73 for HD at the time of writing.
<h3>Home Depot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746479725_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Home Depot Stock In The Last 10 Years

Timbercreek Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TF#TSX">TF</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.16 by 18.75 percent. This is a 11.76 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $28.57 million which beat the analyst consensus estimate of $27.07 million by 5.55 percent. This is a 16.20 percent increase over sales of $24.59 million the same period last year.

TSX:TF

Timbercreek Financial Q1 Adj. EPS $0.19 Beats $0.16 Estimate, Sales $28.57M Beat $27.07M Estimate

Today the company's board of directors appointed William C. Whitaker, vice president, finance, and director, investor relations, to serve as the company's interim chief financial officer until the board concludes its review process. &nbsp;

Management

Ashland Appoints William C. Whitaker, Vice President, Finance, And Director, Investor Relations, To Serve As The Company's Interim CFO Until The Board Concludes Its Review Process

Press Releases

N2OFF: Save Foods Ltd. (100%) Wins Patent Opposition Filed by ECOLAB in Europe

N2OFF and Solterra Join Forces to Exclusively Co-Develop the Solar PV Market in Albania

N2OFF and Solterra Unite to Pioneer Solar PV Development in Albania

N2OFF and Solterra Announce the Closing of a Definitive Agreement to Develop 196 MWp Battery Storage Projects in Italy

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

Contracts

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

N2OFF Establishes a US Subsidiary for Its Solar PV Operations

N2OFF Secures Definitive Agreement to Commercialize 196 MWp Battery Storage Projects

N2OFF Signs Non-Binding LOI for Potential 380MW Battery Energy Storage Projects

N2OFF Announces Potential to Maximize Investment Opportunity Following New Regulation in Germany

SPRC

American Vanguard Corporation Common Stock ($0.10 Par Value)

American Vanguard

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions

CF Industries Holdings, Inc. Common Stock

CF Industries Holdings

Corteva

Enlightify

Brazil Potash

Intrepid Potash

Mosaic

Scotts Miracle-Gro Company (The) Common Stock

Scotts Miracle Gro

CVR Partners, LP Common Units representing Limited Partner Interests

Comments

N2OFF

N2OFF (NITO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL